Sniffing Out Lung Cancer: Breath Analyzer Moves Closer to Clinical Use

Sniffing Out Lung Cancer: Breath Analyzer Moves Closer to Clinical Use

(MedPage Today) -- Electronic "nose" analysis of exhaled breath achieved 80-90% accuracy for detecting lung cancer in patients with suspicious clinical or radiologic findings, a large prospective study showed. The original eNose (SpiroNose) model...

Can a Breath Test Ferret Out Lung Cancer?

An analysis of exhaled breath, using an electronic nose, demonstrates potential for accurately detecting lung cancer in individuals with suspected disease. Medscape Medical News

One of the most diagnosed cancers in Spain during 2025, according to data published by the Spanish Society of Medical Oncology (SEOM), is lung cancer. In view of this alarming scenario, there is a subspecialty within the Pneumology that is gaining more and more weight, since it has a fundamental role for the prognosis of this disease to improve considerably. This figure is that of the interventionist pulmonologist, professional who, over the yea…

Revolutionary Wearable Stethoscope Transforms Lung Sound Monitoring

A revolutionary advancement in the field of respiratory diagnostics has emerged with the introduction of a wearable stethoscope designed for continuous and accurate lung sound monitoring. This innovative device, developed by a team of researchers, addresses the inherent limitations associated with traditional stethoscopes, which heavily rely on the expertise of the attending clinician and can easily be disrupted by external noises. The wearable …

Analysis of the exhaled air with an electronic “nose” detects lung cancer in patients with suspected clinical or radiological findings with an accuracy of 80%-90%, according to a new study. The initial eNose model (SpiroNose) detected lung cancer with an overall accuracy of 92% in patients with chronic obstructive pulmonary disease (COPD) and 80% [...]

AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States

AccuStem Sciences, Inc. announced plans to launch its microRNA Signature Classifier (MSC) blood test for use in the more than 1.6 million US patients diagnosed each year with nodules as part of current lung cancer screening protocols. [AcuStem Sciences, Inc.] Press Release